Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa ®) and MMRV (ProQuad®) at 18 months of age.

CONCLUSION: This investigation suggested that most large local reactions were causally associated with the Infanrix-hexa® vaccine and that the risk was not greater when ProQuad® and Infanrix-hexa® were administered in the same limb. Given the improved vaccine coverage for hepatitis B, benefit-risk analysis likely still favours ongoing use of Infanrix-hexa® with informed parental consent. PMID: 30269915 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30269915?dopt=Abstract

Source: Vaccine - September 27, 2018 Category: Allergy & Immunology Authors: Kiely M, Billard MN, Toth E, Zafack JG, Landry M, Skowronski DM, De Serres G Tags: Vaccine Source Type: research

Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa ®) and MMRV (ProQuad®) at 18 months of age.

Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa ®) and MMRV (ProQuad®) at 18 months of age.